Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Sitravatinib (MGCD516) (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl.
説明 | Sitravatinib (MGCD516) (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl. |
ターゲット&IC50 | DDR2:0.5 nM, EphA3:1 nM, Mer:2 nM, VEGFR3/FLT4:2 nM, Axl:1.5 nM |
In vitro | MGCD516 (Sitravatinib) is an inhibitor of a closely related spectrum of RTKs including RET, the split RTKs (PDGFR, VEGFR, and KIT), DDR2, TRK family, MET, and AXL. MGCD516 causes the marked blockade of phosphorylation of potential driver RTKs and induced potent anti-proliferative effects in vitro. |
In vivo | Sitravatinib has antitumor activity in nonClinicalal cancer models harboring genetic alterations of sitravatinib targets, including the rearrangement of NTRK, RET, or CHR4q12 amplification. In vivo tumor xenografts, MGCD516 causes the significant suppression of tumor growth. Efficacy of MGCD516 is superior to imatinib and crizotinib, two other well-studied multi-kinase inhibitors with overlapping target specificities, both in vitro and in vivo. |
細胞研究 | Cell lines: DDLS,LS141,and MPNST. Concentrations: 62.5,125,250,500,1000,2000 nM2,000-3,000 cells were plated in 96-well plates in RPMI/DME media with 10% FBS and then treated with the indicated drugs the next day.After 72 hours,media was replaced with 100 μL of media with 10% serum and 10% CCK-8 solution.After 1 hour,the optical density was read at 450 nm to determine viability.Background values from negative control wells without cells were subtracted for final sample quantification.Data was plotted as % cell viability compared to DMSO control. |
動物実験 | Animal Models: ICR/SCID mice. Formulation: 0.5% hydroxypropyl methylcellulose (HPMC) and 0.1% Tween-80 solution (pH 1.4). Dosages: 15 mg/kg. Administration: p.o. |
別名 | MG516, MGCD516 |
分子量 | 629.68 |
分子式 | C33H29F2N5O4S |
CAS No. | 1123837-84-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (79.41 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Sitravatinib 1123837-84-2 Angiogenesis Tyrosine Kinase/Adaptors Discoidin Domain Receptor (DDR) VEGFR FLT Trk receptor c-Kit Ephrin Receptor TAM Receptor RTK PD-1 SCFR DDR1 inhibit VEGFR2 MER immune TRKA Cluster of differentiation antigen 135 Cancer Discoidin Domain Receptor VEGFR3 Inhibitor Vascular endothelial growth factor receptor MG516 Trk Receptor Tropomyosin related kinase receptor CD135 MGCD 516 immunotherapy Macrophages MG-516 MGCD-516 DDR2 MGCD516 VEGFR1 Tyrosine MG 516 Fms like tyrosine kinase 3 FLT3 Axl TRKB KIT kinase CD117 inhibitor